SANTA MONICA - Kite, a Gilead Company , today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen.
– Yescarta Achieved a Complete Metabolic Response of 71% at 3 Months Versus 12% Expected with Historical Standard of Care Controls –
– Results Published in Nature Medicine–
.
Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas Innate Pharma SA (Euronext
Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomasMARSEILLE, France (BUSINESS WIRE) #ANKET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that inter.
– Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin’s lymphoma in the U.S. –– POLARIX trial showed the Polivy combination reduced the risk of disease progression, relapse.